Skip to main content

Advertisement

Table 1 Tumor response of different pathologic subtypes

From: Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China

  AITL ALK unknown ALCL ALK+ ALCL ALK− ALCL ENKL PTCL others PTCL-NOS All
Chidamide alone         
 ORR n (%) 32 (49.23) 4 (44.44) 4 (66.67) 3 (37.50) 5 (15.15) 5 (55.56) 47 (37.30) 100 (39.06)
 CR n (%) 6 (9.23) 1 (11.11) 4 (66.67) 2 (25.00) 2 (6.06) 1 (11.11) 11 (8.73) 27 (10.55)
 PR n (%) 26 (40.00) 3 (33.33) 0 (0.00) 1 (12.50) 3 (9.09) 4 (44.44) 36 (28.57) 73 (28.52)
 DCR n (%) 49 (75.38) 6 (66.67) 5 (83.33) 6 (75.00) 14 (42.42) 6 (66.67) 79 (62.70) 165 (64.45)
Chidamide combined with chemotherapy regimens
 ORR n (%) 25 (71.43) 1 (33.33) 2 (100.00) 1 (14.29) 8 (40.00) 3 (75.00) 25 (44.64) 65 (51. 18)
 CR n (%) 4 (11.43) 0 (0.00) 1 (50.00) 0 (0.00) 2 (10.00) 1 (25.00) 7 (12.50) 15 (11.81)
 PR n (%) 21 (60.00) 1 (33.33) 1 (50.00) 1 (14.29) 6 (30.00) 2 (50.00) 18 (32.14) 50 (39.37)
 DCR n (%) 31 (88.57) 1 (33.33) 2 (100.00) 5 (71.43) 10 (50.00) 4 (100.00) 41 (73.21) 94 (74.02)
Combined with CHOP-like regimens
 ORR n (%) 7 (77.78) 1 (50.00) 0 (0.00) 0 (0.00) 1 (33.33) 2 (100.00) 6 (40.00) 17 (53.13)
 CR n (%) 2 (22.22) 0 (0.00) 0 (0.00) 0 (0.00) 1 (33.33) 1 (50.00) 0 (0.00) 4 (12.50)
 PR n (%) 5 (55.56) 1 (50.00) 0 (0.00) 0 (0.00) 0 (0.00) 1 (50.00) 6 (40.00) 13 (40.63)
 DCR n (%) 9 (100.00) 1 (50.00) 0 (0.00) 1 (100.00) 2 (66.67) 2 (100.00) 11 (73.33) 26 (81.25)
Combined with platinum-containing regimens
 ORR n (%) 9 (75.00) 0 (0.00) 1 (100.00) 0 (0.00) 3 (42.86) 0 (0.00) 9 (37.50) 22 (45.83)
 CR n (%) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 4 (16.67) 4 (8.33)
 PR n (%) 9 (75.00) 0 (0.00) 1 (100.00) 0 (0.00) 3 (42.86) 0 (0.00) 5 (20.83) 18 (37.50)
 DCR n (%) 11 (91.67) 0 (0.00) 1 (100.00) 2 (66.67) 3 (42.86) 0 (0.00) 15 (62.50) 32 (66.67)
Combined with other regimens
 ORR n (%) 9 (64.29) 0 (0.00) 1 (100.00) 1 (33.33) 4 (40.00) 1 (50.00) 10 (58.82) 26 (55.32)
 CR n (%) 2 (14.29) 0 (0.00) 1 (100.00) 0 (0.00) 1 (10.00) 0 (0.00) 3 (17.65) 7 (14.89)
 PR n (%) 7 (50.00) 0 (0.00) 0 (0.00) 1 (33.33) 3 (30.00) 1 (50.00) 7 (41.18) 19 (40.43)
 DCR n (%) 11 (78.57) 0 (0.00) 1 (100.00) 2 (66.67) 5 (50.00) 2 (100.00) 15 (88.24) 36 (76.60)
  1. PTCL-NOS peripheral T cell lymphoma-not otherwise specified, AITL angioimmunoblastic T cell lymphoma, ENKL extranodal natural killer/T cell lymphoma, ALCL anaplastic large cell lymphoma, ORR overall response rate, DCR disease control rate